EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?

Martin Higgins, Veronica Wasef, Andrea Kwakowsky iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020883 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Martin Higgins und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Immunization, Passive. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood–brain barrier (BBB) dysfunction. The APOE4 allele, being the leading genetic risk factor for AD, contributes strongly to these symptoms. This review covers the relationship between APOE4 status and the efficacy of FDA-approved monoclonal antibody (mAb) therapies, namely aducanumab, lecanemab, and donanemab. Across several clinical trials, APOE4 carriers exhibited higher rates of ARIA-E and ARIA-H compared to non-carriers. While the therapies did often meet biomarker endpoints (i.e., reduced amyloid), benefits were only observed in early and mild AD, and cognitive benefits were often marginal. Going forward, experimental apoE4-targeted immunotherapies may ease the burden of APOE4-related pathology. The field is shifting towards a more integrated approach, focusing on earlier interventions, biomarker-driven precision treatment, and improved drug delivery systems, such as subcutaneous injections, receptor-mediated transport, and antibodies with enhanced BBB penetration. As it stands, high treatment costs, limited accessibility, and strict eligibility criteria all stand as barriers to treatment. By integrating the APOE4 genotype into treatment planning and focusing on disease-stage-specific approaches, a safer and more effective means of treating AD could be achieved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesImmunization, PassiveHumansApolipoprotein E4AnimalsAntibodies, MonoclonalUnited StatesBlood-Brain BarrierUnited States Food and Drug AdministrationDrug ApprovalBiomarkers

Stichwörter der Autor:innen

APOE4ARIAAlzheimer’s diseaseAβmAb

Substanzen

Amyloid beta-PeptidesApolipoprotein E4Antibodies, MonoclonalBiomarkers

Autor:innen und Institutionen

  • Pharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, Galway Neuroscience Centre, University of Galway, H91 TK33 Galway, Ir…

ORCID-Profile: Andrea Kwakowsky

Zitieren

APA

Higgins, M., Wasef, V., & Kwakowsky, A. (2026). FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020883

Vancouver

Higgins M, Wasef V, Kwakowsky A. FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020883

BibTeX
@article{Higgins2026,
  author = {Higgins, Martin and Wasef, Veronica and Kwakowsky, Andrea},
  title = {FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020883}
}
Kostenlos starten →